文献速递产科母胎医学

产前皮质类固醇:预期获益与潜在风险评估

Antenatal corticosteroids: an assessment of anticipated benefits and potential risks.
PubMed 文献 · Am J Obstet Gynecol · 2018-04-07

产前皮质类固醇是24-34周有早产风险妊娠的标准治疗。近期试验显示对晚期早产和择期剖宫产有适度获益,对围存活期分娩应与家庭讨论后考虑。但许多有先兆早产的妇女接受皮质类固醇后并未在34周前或足月前分娩,导致相当比例的分娩人群暴露于产前皮质类固醇。

要点

  • 产前皮质类固醇是24-34周有早产风险妊娠的标准治疗。
  • 多数早产相关死亡发生在低资源环境,但皮质类固醇在该环境中的疗效和安全性尚待评估。
  • 大型动物模型和儿童队列中发现了心血管和代谢异常,提示对扩大使用应谨慎。

核心结论

  • 产前皮质类固醇对高资源环境中的高危妊娠的短期获益确实支持其使用,因为多年来发现的风险很少。
  • 但这些晚期效应提示,将产前皮质类固醇扩大使用到24-34周有风险妊娠之外应谨慎。
  • 一种前进方向是开发无创胎儿评估,以识别更宽孕周范围内可能获益的妊娠。

研究设计与样本

  • 原文为综述,评估产前皮质类固醇的预期获益和潜在风险。

主要发现

  • 随机对照试验大约在1990年前进行,妊娠一般大于28周,当时的母婴护理实践与今天不同。
  • 随机对照试验数据也不强烈支持产前皮质类固醇治疗至分娩的最佳间隔为1-7天。
  • 使用大型队列、其中超过85%的高危妊娠接受产前皮质类固醇治疗的流行病学研究,可能高估了产前皮质类固醇的获益。
  • 大型动物模型和暴露于产前皮质类固醇的儿童队列中发现了心血管和代谢异常,与胎儿编程为成人疾病相一致。

关键数值与推荐

  • 产前皮质类固醇是24-34周有早产风险妊娠的标准治疗。
  • 近期试验显示产前皮质类固醇对晚期早产和择期剖宫产有适度获益。
  • 围存活期分娩的产前皮质类固醇应与家庭讨论后考虑。

临床怎么用

  • 产前皮质类固醇是24-34周有早产风险妊娠的标准治疗。
  • 围存活期分娩的产前皮质类固醇应与家庭讨论后考虑。
  • 作者认为,这些晚期效应提示将产前皮质类固醇扩大使用到24-34周有风险妊娠之外应谨慎。
  • 作者提出,一种前进方向是开发无创胎儿评估,以识别更宽孕周范围内可能获益的妊娠。

局限性

  • 随机对照试验大约在1990年前进行,妊娠一般大于28周,当时的母婴护理实践与今天不同。
  • 流行病学研究使用大型队列、其中超过85%的高危妊娠接受产前皮质类固醇治疗,可能高估了产前皮质类固醇的获益。
  • 低资源环境中产前皮质类固醇的疗效和安全性尚待评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antenatal corticosteroids are standard of care for pregnancies at risk of preterm delivery between 24-34 weeks' gestational age. Recent trials demonstrate modest benefits from antenatal corticosteroids for late preterm and elective cesarean deliveries, and antenatal corticosteroids for periviable deliveries should be considered with family discussion. However, many women with threatened preterm deliveries receive antenatal corticosteroids but do not deliver until >34 weeks or at term. The net effect is that a substantial fraction of the delivery population will be exposed to antenatal corticosteroids. There are gaps in accurate assessments of benefits of antenatal corticosteroids because the randomized controlled trials were performed prior to about 1990 in pregnancies generally >28 weeks. The care practices for the mother and infant survival were different than today. The randomized controlled trial data also do not strongly support the optimal interval from antenatal corticosteroid treatment to delivery of 1-7 days. Epidemiology-based studies using large cohorts with >85% of at-risk pregnancies treated with antenatal corticosteroids probably overestimate the benefits of antenatal corticosteroids. Although most of the prematurity-associated mortality is in low-resource environments, the efficacy and safety of antenatal corticosteroids in those environments remain to be evaluated. The short-term benefits of antenatal corticosteroids for high-risk pregnancies in high-resource environments certainly justify antenatal corticosteroids as few risks have been identified over many years. However, cardiovascular and metabolic abnormalities have been identified in large animal models and cohorts of children exposed to antenatal corticosteroids that are consistent with fetal programming for adult diseases. These late effects of antenatal corticosteroids suggest caution for the expanded use of antenatal corticosteroids beyond at-risk pregnancies at 24-34 weeks. A way forward is to develop noninvasive fetal assessments to identify pregnancies across a wider gestational age that could benefit from antenatal corticosteroids.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Jobe AH, Goldenberg RL. Antenatal corticosteroids: an assessment of anticipated benefits and potential risks. Am J Obstet Gynecol. 2018. PMID: 29630886. doi:10.1016/j.ajog.2018.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。